Gyrolab® Bioaffy™ 4000

Biomarker research has accelerated in recent years, driving the development of novel biomarker candidates and panels for the study of a wide range of diseases. Discover how Gyroplex™ panels from Gyros Protein Technologies enable multiple biomarkers to be analyzed using very low volumes of samples. Explore how combining Gyroplex panels with Gyrolab® Bioaffy™ 4000 CD means that goals for assay sensitivity can be met when running biomarker panels such as cytokines.

The development of oligo-based therapeutics is a rapidly growing effort, with a need for improved bioanalysis methods for pharmacokinetic (PK) and pharmacodynamic (PD) analysis. Gyros Protein Technologies presents a feasibility study where a hybridization ligand-binding assay was developed and evaluated for the detection of the anti-sense oligonucleotide (ASO) drug casimersen (Amondys 45™) for the treatment of Duchenne muscular dystrophy (DMD) using two labeled oligonucleotide probes with offline incubation followed by an automated microfluidic method. The investigation shows that offline incubation of the sample and capture probe followed by an automated microfluidic method is effective in generating robust data with minimal labor in a short space of time.

Download this application note to see a study that explores a solution to these challenges, by investigating the utility and performance of analyzing viral vector titer and impurities in a continuous 5-CD run (“Gyroplex® panel”) using the Gyrolab® xPand platform and a combination of Gyrolab kits and assay protocols. Two AAV serotypes (AAV2 and AAV9) plus 3 impurities (host-cell proteins [HCPs], endonuclease, and transferrin) were analyzed for each serotype on one instrument.

The drive to generate preclinical and clinical data from smaller volumes of precious sample has led to considerable developments in sampling methods, In this white paper Gyros Protein Technologies describe the most common methods used for microsampling and their respective advantages and disadvantages, how microsampling is being used in preclinical and clinical studies as well as in diagnostics. Download the white paper below to find out a whole host of biopharmaceutical implications via microsampling.

Building on advances in microfluidics, next-generation immunoassays offer unparalleled capability in automation and miniaturization, generating robust and reproducible results for faster decision-making.

In this eBook, discover the advantages of automated, miniaturized immunoassays across the drug development pathway, from pre-clinical to bioprocessing. Learn about challenges and trends in immunoassay technology and how automated, miniaturized immunoassays can help you maximize productivity across a range of biopharmaceutical applications, including:

• Research and clinical development
• Insulin quantification
• Anti-drug antibody studies
• In-solution affinity determination
• Vaccine development and production
  

In this white paper, Gyros Protein Technologies demonstrates how high-quality reagents from Sino Biological can be used in a high-performance, one-hour microfluidic, nanoliterscale immunoassay using Gyrolab® platform for the qualitative detection of total antibodies generated against the receptor binding domain (RBD) of the spike protein of SARS-CoV-2 in human serum samples.

Download it below to explore details of the miniaturized, microfluidic SARS-CoV-2 antibody immunoassay development and learn more about the future directions for Gyrolab assay development to detect SARS-CoV-2 antibodies.

In this video, Gyros Protein Technologies demonstrates how Gyrolab® Bioaffy™ CDs enable seamless assay transfer with precision and reproducibility. Learn how the proprietary CD technology, engineered with highly reproducible nanoliter microfluidics, simplifies assay workflows by eliminating incubations and shortening run times.

Watch this presentation by Chris Fox, applications scientist R&D, at Gyros Protein Technologies, titled: Extended sensitivity for PK/PD and biomarker analysis using nanoliter-scale immunoassays. This talk was presented at the SelectScience® Virtual Analytical Summit 2021.

Experts share how commitment to bioanalytical innovation and quality has enabled success in biotherapeutic development

The Collaboration is poised to deliver a range of ready-to-use bioprocess impurity reagent sets

EMD Serono senior scientist Carina Carter shares her experience with some of the latest immunoassay technology optimizing pharmacokinetics and immunogenicity assay development